Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET

Company Participants

Trista Morrison - Chief Corporate Affairs Officer
Alfred Sandrock - Chief Executive Officer
Toby Ferguson - Chief Medical Officer
Nathan Jorgensen - Chief Financial Officer
Todd Carter - Chief Scientific Officer

Conference Call Participants

Jack Allen - Robert W. Baird & Co.
Divya Rao - TD Cowen
Ry Forseth - Guggenheim Securities
Mehdi Goudarzi - Truist Securities
Sumant Kulkarni - Canaccord Genuity
Kuan-Hung Lin - Wells Fargo Securities
Laura Chico - Wedbush Securities

Operator

Good afternoon, and welcome to the Voyager Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. Please note that today's call is being recorded. A replay of today's call will be available on the Investors section of the company website approximately two hours after completion of this call.

I would now like to turn the call over to Trista Morrison, Chief Corporate Affairs Officer at Voyager.

Trista Morrison

Thank you, and good afternoon. We issued our second quarter 2024 financial results press release this afternoon. The press release and 10-Q are available on our website. Joining me on today's call are Dr. Al Sandrock, our Chief Executive Officer; Dr. Toby Ferguson, our Chief Medical Officer; and Dr. Nathan Jorgensen, our Chief Financial Officer. We will also be joined for the Q&A portion of the call by Dr. Todd Carter, our Chief Scientific Officer.

Before we get started, I'd like to remind everyone that during this call, Voyager representatives may make forward-looking statements as noted in Slide 2 of today's deck. These statements are based on our current expectations and beliefs. They are subject to risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings, which are available on our website for additional detail.

And now, I will turn the call over to Al.

Alfred Sandrock

Good afternoon, everyone, and thank you for joining us. Please turn to Slide 3. At Voyager, we are leveraging the power of human genetics to discover and develop transformative medicines that address the root cause of neurological diseases. We have made tremendous progress toward this goal in 2024, including the achievement of several important milestones in the second quarter.

In May, we dosed the first healthy volunteers in the Phase Ia single ascending dose trial of VY7523, formerly called VY-TAU01, our anti-tau antibody designed to inhibit the spread of pathological tau in Alzheimer's disease. Enrollment in this study is on track and we expect to report topline safety and pharmacokinetic data in the first half of next year. Toby will provide additional detail on our tau-directed programs in just a bit.